ArticleCancer research2026

Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass.

Sarah Kolitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.